◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Tema Heart & Health ETF (HRTS) ETF Overview

Name: Tema Heart & Health ETF (HRTS) price history and fund statistics
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Price history, fund statistics and profile — an exchange-traded fund.

Exchange-Traded Funds · Health · DATA UPDATED 2026-08-31

Tema Heart & Health ETF (HRTS) is an exchange-traded fund managed by Tema ETFs in the "Health" category. It manages roughly $54 million in assets.

Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions.

Interactive chart & fund stats →

HRTS Fund Statistics

Expense ratio	0.75%
Trailing yield	1.30%
Assets under management	$54 million
Fund category	Health
Fund family	Tema ETFs
Inception	2023-11-20

The live price chart, fund profile and news are in the interactive HRTS viewer.

Other Companies in Health

SURI · Simplify Propel Opportunities ETF — $78 million
IBBQ · Invesco Nasdaq Biotechnology ETF — $76 million
HTEC · Robo Global Healthcare Technology and Innovation ETF — $69 million
OZEM · Roundhill Glp-1 & Weight Loss ETF — $61 million
BBC · Virtus LifeSci Biotech Clinical Trials ETF — $46 million
FMED · Fidelity Disruptive Medicine ETF — $45 million
MEDI · Harbor Health Care ETF — $41 million
HELX · Franklin Genomic Advancements ETF — $29 million

← HRTG All “H” companies HRTX →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.